Last reviewed · How we verify
GAMALINE®
GAMALINE is a medication used to treat attention deficit hyperactivity disorder (ADHD).
GAMALINE is a medication used to treat attention deficit hyperactivity disorder (ADHD). Used for Attention deficit hyperactivity disorder (ADHD).
At a glance
| Generic name | GAMALINE® |
|---|---|
| Also known as | GAMALINE® BATCH 8663A0 MS 1.1860.0061.002-9 |
| Sponsor | Phytopharm Consulting Brazil |
| Drug class | Central nervous system stimulant |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
GAMALINE is a central nervous system stimulant that works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine, which help to improve focus, attention, and impulse control.
Approved indications
- Attention deficit hyperactivity disorder (ADHD)
Common side effects
- Nervousness
- Insomnia
- Headache
- Dry mouth
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GAMALINE® CI brief — competitive landscape report
- GAMALINE® updates RSS · CI watch RSS
- Phytopharm Consulting Brazil portfolio CI